Desmopressin: evidence, FDA status and research

A hormone drug for excess urine, bleeding disorders and bedwetting. Controlled trials back those uses; the online memory-booster claim has no support.

Sold for

Desmopressin surfaces online as a memory booster and a nootropic because vasopressin acts in the brain, and as a shortcut for night-time urination; none of that is on the label.

Studies say

Approval for diabetes insipidus, bleeding disorders and nocturia rests on controlled trials and decades of use, an A for those indications, while the only consistent safety story is dangerously low sodium when fluid intake is not restricted.

Why grade A. Desmopressin has been the standard treatment for central diabetes insipidus for nearly fifty years, and the nocturia indications were approved in 2017 and 2018 on randomized placebo-controlled trials summarized on their labels. The citations here are labels and regulatory records, not primary trial papers; the largest trial they describe is Nocdurna's three-month study in 237 women. ²³

FDA. Desmopressin is FDA-approved, first in 1978 as DDAVP, for central diabetes insipidus, for temporary excessive urination after pituitary surgery or head injury, for bleeding control in mild hemophilia A and type 1 von Willebrand disease, and for primary nocturnal enuresis (bedwetting) in children; Nocdurna, a sublingual tablet approved in 2018, treats nocturia due to nocturnal polyuria in adults. The Noctiva nasal spray approved in 2017 for nocturia has been discontinued, and the Stimate nasal spray for bleeding disorders was recalled in 2020 and was still off the market in 2023. ²³¹⁴

Written from 4 cited sources. Fact-checked 2026-10-27: 16 claims checked, 5 corrected. Last refreshed 2026-10-27. Not physician reviewed.

What this means for you

What people take it for: Excess urine, bleeding disorders, bedwetting, and night-time urination.
Can a US doctor prescribe it?: Yes, FDA approved for diabetes insipidus, some bleeding disorders, bedwetting and night-time urination.
Properly tested in people?: Yes, in large controlled trials for its approved uses. The largest trial in the article had 237 women.

Evidence checklist

Randomised controlled trial Placebo-controlled trials for nocturiayes
Human study over 100 people Trial sizes not given in the citationsno information
More than one research group Used and studied for decades across settingsyes
Clinical outcomes, not surrogate markers Urine output, night voids, factor VIII levelsyes
Human safety data beyond case reports Boxed warning for low sodiumyes

Drawn from the cited studies below. A dash means the sources give no information.

What it is

Desmopressin is a lab-made version of vasopressin, also called antidiuretic hormone. Vasopressin is a nine-amino-acid peptide from the pituitary. It tells the kidneys to hold on to water. Two changes were made to create desmopressin. One end lost an amino group. L-arginine was swapped for D-arginine. These changes make the drug last longer. They also strip out most of vasopressin's power to raise blood pressure. The drug acts mainly on the kidney. ²

It has been sold in the United States since 1978 as DDAVP. DDAVP comes as an injection, nasal spray and tablet, and there are generics. Later products followed. Stimate is a high-concentration nasal spray for bleeding disorders. Noctiva is a low-dose nasal spray for nocturia. It was approved in 2017 and has since been discontinued. Nocdurna is a tablet that dissolves under the tongue. It was approved in 2018 for nocturia. ²¹³

How it works

Desmopressin binds vasopressin V2 receptors in the collecting ducts of the kidney. This moves water channels (aquaporins) into the cell membrane. Water is then taken back into the body, and urine becomes more concentrated. In central diabetes insipidus, the pituitary fails to make vasopressin. Desmopressin replaces the missing signal. In nocturia and bedwetting, it cuts the amount of urine made overnight. ²⁴

The same V2 receptor sits on cells lining blood vessels. It triggers release of stored von Willebrand factor and factor VIII. So a dose before a procedure can raise clotting-factor levels several times over. This works in people with mild hemophilia A or type 1 von Willebrand disease. ²⁴

What human research shows

The DDAVP label describes controlled studies in central diabetes insipidus. They showed less urine output and more concentrated urine. It also describes studies in hemophilia A and von Willebrand disease. In those, factor VIII activity rose high enough for minor surgery. This held for patients whose baseline level is above 5%. ²

Nocdurna's approval rested on two randomized placebo-controlled trials. Each lasted three months. One enrolled 237 women and one enrolled 230 men. All woke at least twice a night to urinate. Both trials showed fewer night-time trips to the toilet than placebo. They also showed more nights with one trip or none. The gain over placebo was modest. The label sets different doses for men and women. Women are more prone to low sodium. ³

Study	Model	Finding
DDAVP prescribing information	Regulatory summary of controlled studies in diabetes insipidus and bleeding disorders	Reduces urine volume in central diabetes insipidus; raises factor VIII and von Willebrand factor in mild hemophilia A and type 1 von Willebrand disease. ²
Nocdurna prescribing information	Humans, two randomized placebo-controlled trials in adults with nocturia	Fewer night-time voids than placebo; boxed warning for hyponatremia. ³
Stimate recall, 2020	Regulatory action, Ferring US	Manufacturing suspended and nasal sprays recalled over a seal defect that let the solution evaporate and concentrate; still unavailable in 2023. ⁴

Safety

The one serious risk is hyponatremia, or low blood sodium. It happens when desmopressin stops the kidneys from passing water and the person keeps drinking. Severe cases cause seizures, coma and death. Nocdurna carries a boxed warning for it, as Noctiva did. The label requires a sodium check before starting and within the first week. It bars use in people with kidney impairment, heart failure or uncontrolled hypertension. It also bars use with loop diuretics and with systemic or inhaled glucocorticoids. ³¹

The same rule applies to the older approved uses. Fluid intake must be limited in the hours around a dose. This matters most for children treated for bedwetting and for elderly patients. Nasal forms can cause congestion and nosebleeds. The 2020 Stimate recall followed a packaging seal problem. The seal let the solution evaporate. Patients could then get a higher concentration of desmopressin than the label stated. Headache, nausea and facial flushing are the common minor effects. ²⁴

Questions for your clinician

How will my sodium be checked before and after I start?
Do my kidneys, heart or medicines raise the hyponatremia risk?
What fluid limits should I follow while taking it?

Questions people ask

Is desmopressin FDA-approved?

Yes, since 1978. Approved uses include central diabetes insipidus, post-surgical polyuria, mild hemophilia A, type 1 von Willebrand disease and childhood bedwetting. The Nocdurna tablet is approved for adult nocturia. ²³

What happened to Noctiva and Stimate?

Noctiva, the 2017 nocturia nasal spray, was discontinued by its maker. Stimate is the nasal spray for bleeding disorders. It was recalled in 2020 after a seal defect let the solution evaporate and concentrate. It was still unavailable in 2023. That year a compounding facility was making a substitute nasal spray. ¹⁴

Why is low sodium the main warning?

Desmopressin stops the kidneys from passing water. If a person keeps drinking normally, the held water dilutes blood sodium. Severe dilution causes seizures. The nocturia products carry a boxed warning and require sodium checks. ³

Does desmopressin improve memory?

Vasopressin does act in the brain. That is where the nootropic claim comes from. But desmopressin was built to act on the kidney. No memory use has been studied to the point of approval. None of the cited sources address it. ²

Citations

Drugs.com: Noctiva (desmopressin nasal spray), discontinued drugs.com
DDAVP (desmopressin acetate) prescribing information drugs.com
Nocdurna (desmopressin acetate sublingual tablets) prescribing information drugs.com
National Bleeding Disorders Foundation: updates on the desmopressin nasal spray recall bleeding.org